Secure Asset Management LLC Grows Position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)

Secure Asset Management LLC increased its stake in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) by 9.3% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 39,920 shares of the company’s stock after acquiring an additional 3,406 shares during the period. Secure Asset Management LLC owned about 0.08% of Mirum Pharmaceuticals worth $1,651,000 as of its most recent SEC filing.

Other institutional investors have also recently modified their holdings of the company. Amalgamated Bank boosted its holdings in Mirum Pharmaceuticals by 60.8% in the second quarter. Amalgamated Bank now owns 1,357 shares of the company’s stock valued at $46,000 after acquiring an additional 513 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Mirum Pharmaceuticals by 22.6% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,725 shares of the company’s stock valued at $67,000 after purchasing an additional 318 shares during the last quarter. Avanza Fonder AB bought a new stake in shares of Mirum Pharmaceuticals in the 4th quarter worth approximately $189,000. ProShare Advisors LLC purchased a new stake in shares of Mirum Pharmaceuticals in the 2nd quarter worth approximately $213,000. Finally, Y Intercept Hong Kong Ltd bought a new position in Mirum Pharmaceuticals during the 3rd quarter valued at approximately $215,000.

Analysts Set New Price Targets

Several equities research analysts have commented on MIRM shares. Robert W. Baird boosted their target price on Mirum Pharmaceuticals from $44.00 to $50.00 and gave the stock an “outperform” rating in a report on Wednesday, November 13th. HC Wainwright reiterated a “buy” rating and issued a $66.00 price target on shares of Mirum Pharmaceuticals in a research note on Wednesday, November 13th. Leerink Partners raised their price objective on shares of Mirum Pharmaceuticals from $47.00 to $49.00 and gave the company an “outperform” rating in a research note on Thursday, October 17th. Finally, Citigroup upped their target price on shares of Mirum Pharmaceuticals from $65.00 to $68.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. Ten investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Mirum Pharmaceuticals currently has a consensus rating of “Buy” and a consensus target price of $57.10.

Insider Transactions at Mirum Pharmaceuticals

In related news, insider Joanne Quan sold 6,969 shares of Mirum Pharmaceuticals stock in a transaction that occurred on Friday, January 17th. The stock was sold at an average price of $45.86, for a total transaction of $319,598.34. Following the transaction, the insider now owns 5,649 shares in the company, valued at approximately $259,063.14. This trade represents a 55.23 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Christopher Peetz sold 7,489 shares of the firm’s stock in a transaction on Tuesday, January 7th. The stock was sold at an average price of $42.82, for a total value of $320,678.98. Following the sale, the chief executive officer now directly owns 119,359 shares of the company’s stock, valued at approximately $5,110,952.38. This trade represents a 5.90 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 19,706 shares of company stock worth $875,697 over the last three months. 22.87% of the stock is currently owned by insiders.

Mirum Pharmaceuticals Stock Up 4.1 %

NASDAQ:MIRM opened at $48.65 on Friday. The company’s 50-day simple moving average is $43.65 and its 200-day simple moving average is $41.40. The company has a debt-to-equity ratio of 1.33, a quick ratio of 3.15 and a current ratio of 3.34. Mirum Pharmaceuticals, Inc. has a fifty-two week low of $23.14 and a fifty-two week high of $49.27. The stock has a market capitalization of $2.34 billion, a P/E ratio of -24.08 and a beta of 0.98.

Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.15. Mirum Pharmaceuticals had a negative return on equity of 41.22% and a negative net margin of 31.69%. The business had revenue of $90.38 million for the quarter, compared to the consensus estimate of $81.99 million. During the same period in the prior year, the firm posted ($0.57) earnings per share. The business’s quarterly revenue was up 89.4% on a year-over-year basis. On average, equities analysts anticipate that Mirum Pharmaceuticals, Inc. will post -1.45 earnings per share for the current fiscal year.

Mirum Pharmaceuticals Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.